Bridge Biotherapeutics Rebrands as Parataxis Korea, Pivots to Digital Assets

robot
Abstract generation in progress

Bridge Biotherapeutics changed its name to Parataxis Korea and is shifting its focus to a digital asset treasury business. The move follows a sale of management rights and a business restructuring after the failure of the company’s core biotech pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments